Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, and China. More Details
Excellent balance sheet and fair value.
Share Price & News
How has Vicplas International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 569's share price has been volatile over the past 3 months.
7 Day Return
SG Medical Equipment
1 Year Return
SG Medical Equipment
Return vs Industry: 569 underperformed the SG Medical Equipment industry which returned 404.3% over the past year.
Return vs Market: 569 exceeded the SG Market which returned -21.4% over the past year.
Price Volatility Vs. Market
How volatile is Vicplas International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Rely On Vicplas International's (SGX:569) Earnings Growth?
3 weeks ago | Simply Wall StVicplas International Ltd (SGX:569) Stocks Pounded By 44% But Not Lagging Market On Growth Or Pricing
1 month ago | Simply Wall StShareholders of Vicplas International (SGX:569) Must Be Delighted With Their 423% Total Return
Is Vicplas International undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 569 (SGD0.32) is trading below our estimate of fair value (SGD0.79)
Significantly Below Fair Value: 569 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 569 is poor value based on its PE Ratio (32x) compared to the XA Medical Equipment industry average (31.8x).
PE vs Market: 569 is poor value based on its PE Ratio (32x) compared to the SG market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 569's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 569 is good value based on its PB Ratio (2.6x) compared to the SG Medical Equipment industry average (6.3x).
How is Vicplas International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vicplas International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Vicplas International is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Vicplas International competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Vicplas International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 569 has a large one-off gain of SGD1.9M impacting its July 31 2020 financial results.
Growing Profit Margin: 569's current net profit margins (5.4%) are higher than last year (5.1%).
Past Earnings Growth Analysis
Earnings Trend: 569's earnings have declined by 5% per year over the past 5 years.
Accelerating Growth: 569's earnings growth over the past year (17.4%) exceeds its 5-year average (-5% per year).
Earnings vs Industry: 569 earnings growth over the past year (17.4%) underperformed the Medical Equipment industry 19.7%.
Return on Equity
High ROE: 569's Return on Equity (7.9%) is considered low.
How is Vicplas International's financial position?
Financial Position Analysis
Short Term Liabilities: 569's short term assets (SGD49.5M) exceed its short term liabilities (SGD23.2M).
Long Term Liabilities: 569's short term assets (SGD49.5M) exceed its long term liabilities (SGD6.2M).
Debt to Equity History and Analysis
Debt Level: 569's debt to equity ratio (14%) is considered satisfactory.
Reducing Debt: 569's debt to equity ratio has increased from 3.7% to 14% over the past 5 years.
Debt Coverage: 569's debt is well covered by operating cash flow (140.2%).
Interest Coverage: 569's interest payments on its debt are well covered by EBIT (9.8x coverage).
What is Vicplas International current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 569's dividend (1.19%) isn’t notable compared to the bottom 25% of dividend payers in the SG market (2.44%).
High Dividend: 569's dividend (1.19%) is low compared to the top 25% of dividend payers in the SG market (5.36%).
Stability and Growth of Payments
Stable Dividend: 569 is not paying a notable dividend for the SG market, therefore no need to check if payments are stable.
Growing Dividend: 569 is not paying a notable dividend for the SG market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 569 is not paying a notable dividend for the SG market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 569's dividend in 3 years as they are not forecast to pay a notable one for the SG market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Liang Cheng (65 yo)
Mr. Liang Cheng has been Group Chief Executive Officer of Vicplas International Ltd since November 1, 2018 having served as its Acting Chief Executive Officer since October 31, 2014 and also is responsibl ...
|Group Chief Executive Officer||6yrs||no data||4.72% |
|Chief Financial Officer||4.5yrs||no data||no data|
|Group Operations Director||5.5yrs||no data||no data|
|Technical Director||5.42yrs||no data||no data|
|President of Medical Devices Segment||4.75yrs||no data||no data|
|Company Secretary||8.58yrs||no data||no data|
Experienced Management: 569's management team is seasoned and experienced (5.5 years average tenure).
|Non-Executive Independent Director||10.42yrs||no data||0.63% |
|Non-Executive Director||3.92yrs||no data||0.98% |
|Non-Executive Independent Chairman||11.08yrs||no data||1.97% |
|Non-Executive Director||7yrs||no data||0.59% |
Experienced Board: 569's board of directors are considered experienced (8.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Vicplas International Ltd's company bio, employee growth, exchange listings and data sources
- Name: Vicplas International Ltd
- Ticker: 569
- Exchange: SGX
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: S$160.057m
- Shares outstanding: 508.12m
- Website: https://www.vicplas.com
- Vicplas International Ltd
- 35 Joo Koon Circle
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|569||SGX (Singapore Exchange)||Yes||Ordinary Shares||SG||SGD||Apr 1999|
Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, and China. It manufactures and distributes piping sy ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/21 12:49|
|End of Day Share Price||2020/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.